Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates
暂无分享,去创建一个
K. Scearce-Levie | K. Gadkar | J. Ernst | J. Atwal | Janice A. Maloney | K. Hoyte | Yanmei Lu | R. Watts | M. Dennis | Kristin R. Wildsmith | N. Bien-ly | Y. J. Yu | D. Bumbaca | Raymond K. Tong | Yin Zhang | Jessica A. Couch | M. Hersom | Christine Tan | William J. Meilandt | W. Luk | Maria Hersom | K. Wildsmith | Nga Bien-ly | Daniela Bumbaca | Kwame Hoyte
[1] R. Vassar,et al. Targeting the β secretase BACE1 for Alzheimer's disease therapy , 2014, The Lancet Neurology.
[2] J. Elstrott,et al. Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants , 2014, The Journal of experimental medicine.
[3] Michael D. Ehlers,et al. Breaching the Blood-Brain Barrier for Drug Delivery , 2014, Neuron.
[4] Anirvan Ghosh,et al. Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle , 2014, Neuron.
[5] K. Scearce-Levie,et al. A Therapeutic Antibody Targeting Bace1 Inhibits Amyloid-beta Production in Vivo , 2013 .
[6] R. Watts,et al. Bispecific antibodies for delivery into the brain. , 2013, Current opinion in chemical biology.
[7] K. Scearce-Levie,et al. Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier , 2013, Science Translational Medicine.
[8] R. Watts,et al. Developing Therapeutic Antibodies for Neurodegenerative Disease , 2013, Neurotherapeutics.
[9] É. Hajós‐Korcsok,et al. Cerebrospinal Fluid Amyloid-β (Aβ) as an Effect Biomarker for Brain Aβ Lowering Verified by Quantitative Preclinical Analyses , 2012, Journal of Pharmacology and Experimental Therapeutics.
[10] W. Luk,et al. Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target , 2011, Science Translational Medicine.
[11] K. Scearce-Levie,et al. A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo , 2011, Science Translational Medicine.
[12] B. de Strooper,et al. Inhibition of β-Secretase in Vivo via Antibody Binding to Unique Loops (D and F) of BACE1* , 2011, The Journal of Biological Chemistry.
[13] L. B. Thomsen,et al. Macromolecular drug transport into the brain using targeted therapy , 2010, Journal of neurochemistry.
[14] E. Shusta,et al. Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation , 2007, Pharmaceutical Research.
[15] N. Copeland,et al. Zfp423 Is Required for Normal Cerebellar Development , 2006, Molecular and Cellular Biology.
[16] N. Copeland,et al. A highly efficient recombineering-based method for generating conditional knockout mutations. , 2003, Genome research.
[17] L. Presta,et al. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. , 1996, Protein engineering.